Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 08.09.2021.

#biotech
#immunology
#stockmarket
#loss
#biopharma
#LRcrispr
#equality
#medicalindustry

Companies And Industries

@biospace shared
On Sep 4, 2021
Scopus biopharma flexes immuno-oncology pipeline following its acquisition of Olimmune #immunology #biotech https://t.co/vUP8j3Uqfz
Open
Scopus Biopharma Flexes Immuno-Oncology Pipeline Following Its Acquisition of Olimmune

Scopus Biopharma Flexes Immuno-Oncology Pipeline Following Its Acquisition of Olimmune

​Scopus Biopharma recently launched Duet Therapeutics to integrate its immunotherapy assets' management and clinical development with Olimmune.

@biospace shared
On Sep 2, 2021
Biotech company takes a hit after axing HBV therapy over safety concerns #biotech #stockmarket https://t.co/mFvP0sSQVk
Open
Biotech Company Takes a Hit After Axing HBV Therapy over Safety Concerns

Biotech Company Takes a Hit After Axing HBV Therapy over Safety Concerns

Shares of Assembly Biosciences have fallen more than 20% in premarket trading after the company discontinued the development of a hepatitis B therapeutic candidate.

@FierceBiotech shared
On Sep 3, 2021
“When I first read the allegations, I felt dazed and confused […] But I think what we're currently seeing is no ordinary short seller betting our data will disappoint," Barbier said. Shares were up 9% premarket as the drama continues https://t.co/TUTlJrg1jn
Open
Cassava CEO, ‘dazed and confused’, takes to biotech defense handbook by blaming short sellers for woes

Cassava CEO, ‘dazed and confused’, takes to biotech defense handbook by blaming short sellers for woes

The Cassava saga continues as its chief Remi Barbier has come out, guns blazing, against accusations that the biotech may have deliberately misdirected investors on its recent Alzheimer’s ...

@IAmBiotech shared
On Sep 5, 2021
“Jim Wilson, the famed gene therapy researcher, teamed up with the late Tachi Yamada and Braidwell’s Alex Karnal to launch the Institute for Life Changing Medicines.” https://t.co/vQAgCEPls9
Open
Scoop: Inspired by the late Tachi Yamada, Jim Wilson launches new nonprofit targeting underserved ultra-rare diseases

Scoop: Inspired by the late Tachi Yamada, Jim Wilson launches new nonprofit targeting underserved ultra-rare diseases

A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at delivering therapies to rare disease populations they believe pharma is leaving behind. ...

@biospace shared
On Sep 7, 2021
@ExelixisInc mourns loss of two veteran execs #biopharma #loss https://t.co/rG3x6kVHL6
Open
Exelixis Mourns Loss of Two Veteran Execs

Exelixis Mourns Loss of Two Veteran Execs

Exelixis is mourning the loss of two veteran executives—Dr. Gisela M. Schwab, president, Product Development and Medical Affairs and CMO, and Jon Berndt, senior VP of Sales.  

@Labroots shared
On Sep 3, 2021
Labroots invites you to the 4th Annual CRISPR Virtual Event! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision in gene editing & using CRISPR for drug discovery. Register here: https://t.co/ygDLTxHJxP #LRcrispr https://t.co/5iezDA1umt
Open
CRISPR 2021

CRISPR 2021

Labroots invites you to the 4th Annual CRISPR Virtual Event ! This event will continue the conversation of the abilities of CRISPR-based editing

@FierceBiotech shared
On Sep 2, 2021
Kim has been the face of the study, talking investors through its design and objectives on a conference call last month after the FDA cleared Avidity to start the rare disease clinical trial https://t.co/mjgxIItf4H
Open
Exit of Avidity CMO on cusp of first clinical trial sparks stock rout

Exit of Avidity CMO on cusp of first clinical trial sparks stock rout

Investors are taking the departure of Avidity Biosciences’ chief medical officer badly. After learning Jae Kim had left for personal reasons, just days after giving his notice and on the ...

@biospace shared
On Sep 2, 2021
Kyowa Kirin: Tilting at gender equality at the highest levels #equality #medicalindustry https://t.co/d61eMFOo8o
Open
Kyowa Kirin: Tilting at Gender Equality at the Highest Levels

Kyowa Kirin: Tilting at Gender Equality at the Highest Levels

Between April 2020 and today, the executive board of Kyowa Kiran North America (KKNA) has grown from being predominantly male to a 50/50 gender split.